Edition:
India

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,158JPY
7:52am IST
Change (% chg)

¥20 (+0.48%)
Prev Close
¥4,138
Open
¥4,177
Day's High
¥4,177
Day's Low
¥4,125
Volume
3,185,500
Avg. Vol
6,822,268
52-wk High
¥4,562
52-wk Low
¥2,894

Select another date:

Sat, May 23 2020

BRIEF-U.S. FDA Approves Takeda's Alunbrig As A First-Line Treatment For Patients With Rare Form Of Lung Cancer

* U.S. FDA APPROVES TAKEDA’S ALUNBRIG® (BRIGATINIB) AS A FIRST-LINE TREATMENT OPTION FOR PATIENTS DIAGNOSED WITH RARE AND SERIOUS FORM OF LUNG CANCER

Takeda says coronavirus treatment trial using recovered patients' blood could start in July

Takeda Pharmaceutical Co Ltd could start a clinical trial as early as July for a potential treatment of COVID-19 that is based on antibodies from recovered patients' blood, company executives said on Wednesday.

Takeda says coronavirus treatment trial using recovered patients' blood could start in July

Takeda Pharmaceutical Co Ltd could start a clinical trial as early as July for a potential treatment of COVID-19 that is based on antibodies from recovered patients' blood, company executives said on Wednesday.

Takeda says coronavirus treatment trial using recovered patients' blood could start in July

May 13 Takeda Pharmaceutical Co Ltd could start a clinical trial as early as July for a potential treatment of COVID-19 that is based on antibodies from recovered patients' blood, company executives said on Wednesday.

Takeda Pharma logs surprise profit, updates on COVID-19 therapy

TOKYO/NEW YORK Takeda Pharmaceutical Co booked a surprise operating profit and forecast that income would triple this business year as hefty acquisition costs related to last year's $59 billion Shire takeover recede.

UPDATE 4-Takeda Pharma logs surprise profit, updates on COVID-19 therapy

TOKYO/NEW YORK, May 13 Takeda Pharmaceutical Co booked a surprise operating profit and forecast that income would triple this business year as hefty acquisition costs related to last year's $59 billion Shire takeover recede.

Takeda Pharma posts full-year operating profit amid Shire consolidation

TOKYO, May 13 Takeda Pharmaceutical Co Ltd said on Wednesday it had posted a full-year operating profit, surprising analysts who had expected it to make a loss on the hefty costs that came with last year's $59 billion takeover of Shire Plc.

BRIEF-Phathom Pharma On May 5, Entered Into A Commercial Supply Agreement With Takeda Pharmaceutical Company Limited

* PHATHOM PHARMACEUTICALS INC - ON MAY 5, ENTERED INTO A COMMERCIAL SUPPLY AGREEMENT WITH TAKEDA PHARMACEUTICAL COMPANY LIMITED

BRIEF-Takeda Announces U.S. FDA Breakthrough Therapy Designation For Mobocertinib (TAK-788)

* TAKEDA ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR MOBOCERTINIB (TAK-788) FOR THE TREATMENT OF NSCLC PATIENTS WITH EGFR EXON 20 INSERTION MUTATIONS

Japan's Takeda sells $670 million of Europe OTC assets to pare debt

TOKYO Japan's Takeda Pharmaceutical Co Ltd said it would sell up to $670 million of over-the-counter drug operations in Europe to pare debt ahead of its full-year earnings announcement.

Select another date: